Events

Please join us at the following conferences and events. Stop by our booth, or get in touch to arrange a meeting.

From Micrograms to Many, Antibody Protein Sequencing to Maintain Anti-CD42a Clone ESS

How to Choose an Antibody CRO

An Introduction to Recombinant Antibody Technology for Diagnostic Applications

Improve your Flow Cytometry with FIX&PERM® Buffers and Recombinant Engineered Antibodies

Anti-CD47 Antibodies: A Promising Approach for Cancer Immunotherapy

PD-L1 and PD-L2: PD-1 Ligands in Cancer Immunotherapy

Applying Recombinant Antibody Engineering to Further Immunoassay Development

Latest Advancements in Antibody Engineering – Bispecifics, Diagnostic Controls, and More

VivopureX™ Microgrant Winners Announced

A Question of Isotype: How Switching Antibody Isotypes and Fc Regions Promotes Discovery

Advancing Cancer Immunotherapy: A Closer Look at Anti-VISTA Antibodies

9 Questions to Consider Before Your Next Antibody Engineering Project

Selecting the Right Cell Line to Empower Your Cancer Antibody Research

Collaborating on an Antibody Match Pair for COVID-19 Research

Supporting Cancer Immunotherapy Research: Recombinant, Syngeneic Antibodies Against Mouse PD-1

An Introduction to Absolute Antibody Custom Services

Submit Your VivopureX™ Research Proposal to Earn a Research Microgrant from Absolute Antibody

Science Showcase: All About the Antibodies

Engineering Antibody Reagents to Facilitate In Vivo Research

Comparing potential bispecific formats of trastuzumab and a humanized OKT3

Converting a Popular Puromycin Antibody to Recombinant Production

Antibody Humanization for Infectious Disease Serological Assay Development

Supporting Alzheimer’s Research: Recombinant Antibodies Against Amyloid Beta

PEGS Europe – Booth #1310

5-7th November 2024

Barcelona, Spain

Biologics UK – Booth #32

13-15th March 2024

London, UK

Recombinant Antibodies Against Influenza A Virus Subtype H5N1

Engineered Mouse-Ly-6G Antibody Shows Near Complete Neutrophil Depletion In Vivo

Recombinant Engineered Human Cytomegalovirus Antibodies

Respiratory Syncytial Virus (RSV) Antibodies

Comparing potential bispecific formats comprising of trastuzumab and a humanized OKT3